ID   KOPN-63
AC   CVCL_A333
SY   Kopn-63; KOPN63; Kopn63
DR   cancercelllines; CVCL_A333
DR   IARC_TP53; 2684
DR   IARC_TP53; 28419
DR   Wikidata; Q54900320
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8289498;
RX   PubMed=10360377;
RX   PubMed=10490826;
RX   PubMed=10995006;
RX   PubMed=20519628;
RX   PubMed=20575032;
RX   PubMed=29786757;
RX   PubMed=35124168;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; HGNC:8632; PBX1 + HGNC; HGNC:11633; TCF3; Name(s)=TCF3-PBX1, E2A-PBX1 (PubMed=29786757).
CC   Sequence variation: Mutation; HGNC; HGNC:12766; NSD2; Simple; p.Glu1099Lys (c.3295G>A); ClinVar=VCV000638278; Zygosity=Heterozygous (PubMed=35124168).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg209fs (c.627_632del6ins10); Zygosity=Hemizygous (PubMed=8289498).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20575032).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly293fs (c.879_880insCC); Zygosity=Unspecified (PubMed=20575032).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
DI   ORDO; Orphanet_585956; B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   12Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 19
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=8289498;
RA   Wada H., Asada M., Nakazawa S., Itoh H., Kobayashi Y., Inoue T.,
RA   Fukumuro K., Chan L.C., Sugita K., Hanada R., Akuta N., Kobayashi N.,
RA   Mizutani S.;
RT   "Clonal expansion of p53 mutant cells in leukemia progression in
RT   vitro.";
RL   Leukemia 8:53-59(1994).
//
RX   PubMed=10360377; DOI=10.1038/sj.leu.2401437;
RA   Nakamura M., Sugita K., Inukai T., Goi K., Iijima K., Tezuka T.,
RA   Kojika S., Shiraishi K., Miyamoto N., Karakida N., Kagami K.,
RA   Koyama-Okazaki T., Mori T., Nakazawa S.;
RT   "p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in
RT   childhood acute lymphoblastic leukemia with 11q23 translocation.";
RL   Leukemia 13:884-890(1999).
//
RX   PubMed=10490826; DOI=10.1038/sj.onc.1202874;
RA   Fu X.-Y., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.;
RT   "EB-1, a tyrosine kinase signal transduction gene, is
RT   transcriptionally activated in the t(1;19) subset of pre-B ALL, which
RT   express oncoprotein E2a-Pbx1.";
RL   Oncogene 18:4920-4929(1999).
//
RX   PubMed=10995006; DOI=10.1038/sj.leu.2401893;
RA   Iijima K., Sugita K., Inukai T., Goi K., Tezuka T., Uno K., Sato H.,
RA   Kagami K., Nakazawa S.;
RT   "Expression of thrombopoietin receptor and its functional role in
RT   human B-precursor leukemia cells with 11q23 translocation or
RT   Philadelphia chromosome.";
RL   Leukemia 14:1598-1605(2000).
//
RX   PubMed=20519628; DOI=10.1182/blood-2009-09-244673;
RA   Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H.,
RA   Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H.,
RA   Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K.,
RA   Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.;
RT   "Aberrant induction of LMO2 by the E2A-HLF chimeric transcription
RT   factor and its implication in leukemogenesis of B-precursor ALL with
RT   t(17;19).";
RL   Blood 116:962-970(2010).
//
RX   PubMed=20575032; DOI=10.1002/ajh.21738; PMCID=PMC7159455;
RA   Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I.,
RA   Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i.,
RA   Tada M., Moriuchi T., Sugita K.;
RT   "A specific linkage between the incidence of TP53 mutations and type
RT   of chromosomal translocations in B-precursor acute lymphoblastic
RT   leukemia cell lines.";
RL   Am. J. Hematol. 85:535-537(2010).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//